Can I Take Ashwagandha with BPC-157?

Why the Combination Is Popular

People recovering from musculoskeletal injuries or managing chronic stress often reach for both BPC-157 and ashwagandha. BPC-157 is a 15-amino-acid fragment of human gastric juice protein that has shown tissue-repair properties in preclinical models. Ashwagandha is an Ayurvedic adaptogen studied for stress resilience and hormonal support.

The Recovery-Plus-Resilience Stack

The logic behind this pairing is straightforward. BPC-157 targets local tissue repair, tendon healing, and gut mucosal integrity through nitric oxide (NO) system modulation and growth factor upregulation [1]. Ashwagandha (Withania somnifera) addresses systemic stress by lowering cortisol and supporting thyroid output [2]. Users combine them expecting faster physical recovery alongside better stress tolerance, sleep quality, and training readiness.

What the Evidence Gap Looks Like

No randomized controlled trial has directly studied BPC-157 co-administered with ashwagandha in humans. BPC-157 human data remains limited to a small number of trials and case series, mostly in GI settings. Ashwagandha has a larger clinical evidence base (over 30 RCTs) but none of those trials included a peptide co-intervention arm. The safety assessment below is built from pharmacological first principles, known mechanisms of each compound, and extrapolation from the existing clinical literature on each agent independently.

Mechanism of Interaction: Pharmacokinetic vs. Pharmacodynamic

The interaction profile between these two compounds is almost entirely pharmacodynamic, not pharmacokinetic. That distinction matters because it shapes monitoring strategy and risk.

Pharmacokinetic Considerations

BPC-157 is a peptide. It is degraded by proteases in the GI tract and does not undergo hepatic cytochrome P450 metabolism [1]. Ashwagandha's withanolides are metabolized by CYP3A4 and CYP2D6, but because BPC-157 bypasses the CYP system entirely, there is no competition for the same metabolic enzymes [3]. Neither compound is a known inducer or inhibitor of P-glycoprotein. A pharmacokinetic drug-drug interaction in the classic sense (altered absorption, distribution, metabolism, or excretion of one compound by the other) is unlikely based on current mechanistic understanding.

Pharmacodynamic Overlap: The HPA Axis

The more relevant consideration is pharmacodynamic. Both compounds influence the hypothalamic-pituitary-adrenal (HPA) axis, though through different entry points.

Ashwagandha directly reduces serum cortisol. A 60-day RCT by Chandrasekhar et al. (N=64) found that 300 mg twice daily of a root extract (KSM-66) lowered serum cortisol by 30.5% compared to placebo (P<0.0001) [2]. BPC-157, in rodent stress models, has shown anti-anxiety and stress-buffering effects, possibly through dopaminergic and serotonergic pathway modulation [4]. If both compounds suppress stress-axis output simultaneously, the theoretical concern is excessive cortisol suppression, though no clinical case report has documented this.

Pharmacodynamic Overlap: Thyroid Function

Ashwagandha can raise serum T4 and lower TSH. A 2018 trial in subclinical hypothyroid patients (N=50) found that 600 mg/day of ashwagandha root extract significantly increased serum T3 and T4 while normalizing TSH over 8 weeks [5]. BPC-157's effects on thyroid function have not been studied in humans, but its broad influence on growth factor signaling and the NO system means a secondary thyroid effect cannot be ruled out. This is the primary reason to monitor thyroid panels when stacking these two compounds.

Dose-Separation Strategy

Because no pharmacokinetic interaction is expected, dose separation serves a practical purpose: reducing GI competition for absorption and allowing clearer attribution if side effects emerge.

Oral BPC-157

Oral BPC-157 is typically dosed at 250 to 500 mcg once or twice daily, taken on an empty stomach to minimize protease exposure. Gastric acid stability is one of BPC-157's distinguishing features among peptides. Sikiric et al. Demonstrated that the pentadecapeptide retains biological activity in acidic environments, a property attributed to its unusual resistance to enzymatic degradation [1].

Oral Ashwagandha

Ashwagandha root extract is commonly dosed at 300 to 600 mg daily, often split into two doses. Most RCTs used the KSM-66 or Sensoril standardized extracts with food [2][6].

Practical Separation Window

Taking BPC-157 on an empty stomach first (fasted, 20 to 30 minutes before breakfast) and ashwagandha with breakfast or a later meal creates a natural 30-to-60-minute separation. This approach also aligns with how each compound was administered in its respective clinical studies. There is no published data showing that simultaneous ingestion is harmful, but separation simplifies troubleshooting if GI discomfort occurs.

Monitoring Protocol for the Combination

Because both compounds can influence endocrine axes, a structured monitoring approach is warranted for anyone using both for more than four weeks.

Baseline Labs (Before Starting)

Draw these before beginning the combination: TSH, free T4, free T3, morning cortisol (drawn between 7:00 and 9:00 AM), DHEA-S, complete metabolic panel (CMP), and CBC. These establish a hormonal and metabolic baseline.

Follow-Up at 8 to 12 Weeks

Repeat TSH, free T4, free T3, and morning cortisol. If TSH drops below 0.4 mIU/L or morning cortisol falls below 5 mcg/dL, reassess the ashwagandha dose before attributing the change to BPC-157. Ashwagandha is the more likely driver of thyroid and cortisol shifts based on existing trial data [5][2].

Symptom Tracking

Watch for signs of excessive cortisol suppression: persistent fatigue, lightheadedness on standing, salt cravings, and low morning energy despite adequate sleep. These may indicate that the combined HPA-axis effect is too aggressive, and ashwagandha dose reduction is the first adjustment to consider.

When to Pause

If free T4 rises above the upper reference range or TSH drops below 0.1 mIU/L, discontinue ashwagandha and recheck labs in 4 to 6 weeks. BPC-157 can typically be continued during this reassessment period, as its thyroid impact is speculative rather than documented.

Testosterone and Ashwagandha: Relevance to the BPC-157 User

Many BPC-157 users are men in their 30s to 50s exploring peptide therapy alongside hormonal optimization. Ashwagandha's effect on testosterone makes this relevant context.

Trial Data on Testosterone

A 2019 RCT by Lopresti et al. (N=57 overweight men, aged 40 to 70) found that 600 mg/day of ashwagandha extract for 8 weeks increased testosterone by approximately 15% compared to placebo, with DHEA-S rising by 18% [6]. An earlier study by Wankhede et al. (N=57 young men) reported a 17% increase in testosterone with 600 mg/day over 8 weeks in resistance-trained subjects [7]. These effects are modest compared to exogenous testosterone but may be additive in someone already using BPC-157 for injury recovery during a training block.

BPC-157 and Testosterone

BPC-157 has not been shown to directly raise testosterone in any published study. Its relevance here is indirect: by supporting tendon and ligament repair, BPC-157 may allow users to maintain training intensity, which itself supports endogenous testosterone production. The combination does not create a hormonal risk beyond what ashwagandha alone produces, but testosterone and DHEA-S should be part of the monitoring panel described above.

Safety Signals and Contraindications

Neither compound has a large adverse-event database, but the available data allows a reasonable safety assessment.

Ashwagandha Safety

A 2021 systematic review of ashwagandha safety across 69 studies (N=over 12,000 participants) found that adverse events were mostly mild and GI-related: nausea, diarrhea, and abdominal discomfort [8]. Rare cases of thyrotoxicosis have been reported in individuals with pre-existing thyroid autoimmunity who took ashwagandha without monitoring [5]. Ashwagandha is contraindicated in pregnancy and should be used cautiously in autoimmune thyroid disease.

BPC-157 Safety

BPC-157 has a favorable preclinical safety profile. Rodent studies at doses far exceeding human-equivalent therapeutic ranges have not identified organ toxicity, mutagenicity, or carcinogenicity [1]. Human safety data is limited. The compound is not FDA-approved and is available through 503A compounding pharmacies in the United States. The FDA issued warning letters to several compounding pharmacies regarding BPC-157 marketing claims in 2023 and 2024 [9].

Combined Use: Who Should Avoid It

Individuals with Graves' disease, Hashimoto's thyroiditis, or other autoimmune thyroid conditions should avoid adding ashwagandha to a BPC-157 regimen without endocrinologist oversight. Patients on thyroid replacement therapy (levothyroxine, liothyronine, or desiccated thyroid) should be aware that ashwagandha may alter their dose requirements. Anyone on corticosteroid therapy or with adrenal insufficiency should consult their prescriber before adding either compound, given the combined cortisol-lowering potential.

What If You Are Already Taking Both?

If you have been using BPC-157 and ashwagandha together without adverse effects, the primary action item is to verify that your thyroid and cortisol levels are within range.

Step-by-Step Self-Audit

First, review your dosing: confirm that ashwagandha is at or below 600 mg/day and BPC-157 is at or below 500 mcg twice daily. Second, get labs drawn if you have not done so within the last 12 weeks. The minimum panel is TSH, free T4, and morning cortisol. Third, assess symptom changes. New-onset insomnia, heart palpitations, or unexplained weight loss could signal thyroid overstimulation from ashwagandha. Persistent fatigue or orthostatic dizziness could signal cortisol suppression.

Adjusting the Stack

If labs are normal and you feel well, no change is needed. If TSH trends downward (even within range), consider reducing ashwagandha to 300 mg/day or cycling it (8 weeks on, 4 weeks off). Cycling ashwagandha is a common practitioner recommendation to prevent thyroid axis adaptation, though no RCT has validated a specific cycling protocol.

The Role of the Compounding Pharmacy

BPC-157 quality varies significantly across compounding pharmacies. This matters for safety assessment because contaminants or degradation products in a poorly compounded peptide could introduce interaction risks that pure BPC-157 would not.

Quality Markers to Verify

Request a Certificate of Analysis (COA) showing peptide purity above 98%, endotoxin testing, and sterility results (for injectable forms). Third-party testing through an ISO 17025-accredited lab adds another layer of verification. Dr. Ryan Smith, a functional medicine physician who prescribes compounded peptides, has noted: "The biggest safety variable in peptide therapy isn't the peptide itself. It's the compounding source. A COA from the pharmacy's own lab is a start, but independent third-party verification is the standard patients should expect."

503A vs. 503B Pharmacies

Section 503A pharmacies compound for individual prescriptions. Section 503B outsourcing facilities compound in larger batches under stricter FDA oversight, including current Good Manufacturing Practice (cGMP) requirements [9]. When possible, sourcing BPC-157 from a 503B facility provides an additional layer of quality assurance.

Clinical Bottom Line

The BPC-157 and ashwagandha combination lacks direct human interaction data, but pharmacological analysis shows no CYP-mediated metabolic conflict and a manageable pharmacodynamic overlap concentrated on the HPA and HPT axes. Baseline and follow-up thyroid and cortisol labs every 8 to 12 weeks, dose separation of 30 to 60 minutes, and awareness of thyroid-related symptoms constitute a practical safety framework. Individuals with autoimmune thyroid disease or adrenal insufficiency should avoid this combination without specialist supervision. For everyone else, current evidence does not support a contraindication to co-use at standard doses (ashwagandha 300 to 600 mg/day; BPC-157 250 to 500 mcg once or twice daily) [1][2][5].